Inventor · disambiguated record
Jack A. Roth
Also filed as: ROTH JACK · ROTH JACK A
40 granted patents·17 pending applications·1,157 citations·filing 1985–2022
98Inventor score
Top patents by PatentIndex Score
57 records- 0197US6511847B1Recombinant p53 adenovirus methods and compositionsUNIV TEXAS·Filed 2000·Granted Jan 28, 2003·46 cites·13 claims
- 0297US6069134AMethods and compositions comprising DNA damaging agents and p53UNIV TEXAS·Filed 1997·Granted May 30, 2000·278 cites·69 claims
- 0396US6143290ATumor regression by adenovirus expression of wild-type p53UNIV TEXAS·Filed 1994·Granted Nov 7, 2000·130 cites·94 claims
- 0496US5747469AMethods and compositions comprising DNA damaging agents and p53UNIV TEXAS·Filed 1994·Granted May 5, 1998·150 cites·105 claims
- 0592US6410010B1Recombinant P53 adenovirus compositionsUNIV TEXAS·Filed 1993·Granted Jun 25, 2002·76 cites·18 claims
- 0687US11278592B2Methods and compositions for TUSC2 immunotherapyUNIV TEXAS·Filed 2017·Granted Mar 22, 2022·2 cites·13 claims
- 0787US8338366B2Bioactive FUS1 peptides and nanoparticle-polypeptide complexesLIN JACKI·Filed 2006·Granted Dec 25, 2012·13 cites·31 claims
- 0886US6630344B1Diminishing viral gene expression by promoter replacementUNIV TEXAS·Filed 2000·Granted Oct 7, 2003·12 cites·29 claims
- 0985US7109179B2Methods and compositions comprising DNA damaging agents and p53UNIV TEXAS·Filed 2004·Granted Sep 19, 2006·15 cites·28 claims
- 1084US5958892A2-methoxyestradiol-induced apoptosis in cancer cellsUNIV TEXAS·Filed 1996·Granted Sep 28, 1999·48 cites·26 claims
- 1181US7244617B2Diminishing viral gene expression by promoter replacementUNIV TEXAS·Filed 2003·Granted Jul 17, 2007·5 cites·28 claims
- 1281US6110744ADiminishing viral gene expression by promoter replacementUNIV TEXAS·Filed 1997·Granted Aug 29, 2000·43 cites·24 claims
- 1381US6017524AInhibiting the growth p53 deficient tumor cells by administering the p53 geneUNIV TEXAS·Filed 1992·Granted Jan 25, 2000·43 cites·41 claims
- 1479US6830749B2Recombinant P53 adenovirus methods and compositionsUNIV TEXAS·Filed 2002·Granted Dec 14, 2004·3 cites·25 claims
- 1579US6410029B12-methoxyestradiol-induced apoptosis in cancer cellsUNIV TEXAS·Filed 1999·Granted Jun 25, 2002·34 cites·26 claims
- 1678US12485159B2Methods and compositions for TUSC2 immunotherapyUNIV TEXAS·Filed 2022·Granted Dec 2, 2025·0 cites·15 claims
- 1778US7902441B2Chromosome 3p21.3 genes are tumor suppressorsUNIV TEXAS·Filed 2003·Granted Mar 8, 2011·4 cites·35 claims
- 1878US6740320B1Recombinant P53 adenovirus methods and compositionsUNIV TEXAS·Filed 1995·Granted May 25, 2004·27 cites·83 claims
- 1976US9675663B2TUSC2 therapiesUNIV TEXAS·Filed 2014·Granted Jun 13, 2017·2 cites·21 claims
- 2076US7033750B2Recombinant P53 adenovirus methods and compositionsUNIV TEXAS·Filed 2002·Granted Apr 25, 2006·2 cites·17 claims
- 2173US8859727B2Bioactive FUS1 peptides and nanoparticle-polypeptide complexesUNIV TEXAS·Filed 2012·Granted Oct 14, 2014·2 cites·18 claims
- 2273US6797702B1Methods and compositions comprising DNA damaging agents and P53UNIV TEXAS·Filed 1997·Granted Sep 28, 2004·22 cites·82 claims
- 2372US6482803B1Modification of mutated P53 gene in tumors by retroviral delivery of ribozyme AUNIV TEXAS·Filed 1995·Granted Nov 19, 2002·35 cites·25 claims
- 2471US6627189B1Inhibition of cellular proliferation using ras antisense moleculesUNIV TEXAS·Filed 1995·Granted Sep 30, 2003·28 cites·14 claims
- 2568US2007190040A1Recombinant p53 adenovirus methods and compositionsZHANG WEI-WEI·Filed 2005·Application pending·0 cites
- 2667US8658778B2hTMC promoter and vectors for the tumor-selective and high-efficient expression of cancer therapeutic genesJI LIN X·Filed 2006·Granted Feb 25, 2014·1 cites·35 claims
- 2766US5637456ARapid test for determining the amount of functionally inactive gene in a gene therapy vector preparationUNIV TEXAS·Filed 1995·Granted Jun 10, 1997·30 cites·20 claims
- 2864US6899870B1Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codeliveryUNIV TEXAS·Filed 1999·Granted May 31, 2005·16 cites·49 claims
- 2963US10293056B1Methods and compositions for non-viral gene therapy for treatment of hyperproliferative diseasesRAMESH RAJAGOPAL·Filed 2000·Granted May 21, 2019·4 cites·38 claims
- 3063US7423015B1Antihelminthic drugs as a treatment for hyperproliferative diseasesUNIV TEXAS·Filed 2002·Granted Sep 9, 2008·2 cites·57 claims
- 3161US9944951B2Chromosome 3p21.3 genes are tumor suppressorsJI LIN·Filed 2011·Granted Apr 17, 2018·0 cites·4 claims
- 3261US2008044386A1Protamine-Adenoviral Vector Complexes and Methods of UseJI LIN·Filed 2007·Application pending·0 cites
- 3360US6805858B1Methods for the administration of adenovirus p53UNIV TEXAS·Filed 1999·Granted Oct 19, 2004·10 cites·70 claims
- 3459US2003099614A12-Methoxyestradiol-induced apoptosis in cancer cellsUNIV TEXAS·Filed 2002·Application pending·0 cites
- 3558US6251871B1P16 expression constructs and their application in cancer therapyUNIV TEXAS·Filed 1997·Granted Jun 26, 2001·13 cites·13 claims
- 3658US2006182718A1Methods and compositions comprising DNA damaging agents and p53ROTH JACK A·Filed 2006·Application pending·0 cites
- 3757US7163925B1p16 expression constructs and their application in cancer therapyUNIV TEXAS·Filed 1998·Granted Jan 16, 2007·12 cites·46 claims
- 3857US6436700B1Anti-sense p21 k-rasUNIV TEXAS·Filed 1992·Granted Aug 20, 2002·10 cites·7 claims
- 3956US7252989B1Adenovirus supervector systemUNIV TEXAS·Filed 1994·Granted Aug 7, 2007·12 cites·22 claims
- 4056US2003083303A1Adenovirus supervector systemUNIV TEXAS·Filed 2002·Application pending·0 cites
- 4155US2016310569A1Tusc2 therapiesUNIV TEXAS·Filed 2016·Application pending·0 cites
- 4255US2002164715A1Chromosome 3p21.3 genes are tumor suppressorsFiled 2001·Application pending·0 cites
- 4353US2012108880A1CHROMOSOME 3p21.3 GENES ARE TUMOR SUPPRESSORSJI LIN·Filed 2012·Application pending·0 cites
- 4452US6998117B1Cancer treatment with retroviral vectors comprising wild-type p53UNIV TEXAS·Filed 1995·Granted Feb 14, 2006·9 cites·38 claims
- 4552US2012244209A1Tusc2 therapiesROTH JACK A·Filed 2012·Application pending·0 cites
- 4651US2015297631A1Tusc2 therapiesUNIV TEXAS·Filed 2015·Application pending·0 cites
- 4751US2006052322A1Combination treatment of cancer with elicitor of gene product expression and gene-product targeting agentINTROGEN THERAPEUTICS INC·Filed 2005·Application pending·0 cites
- 4849US2004028654A1Protamine-adenoviral vector complexes and methods of useUNIV TEXAS·Filed 2003·Application pending·0 cites
- 4946US7977468B2Chromosome 3p21.3 genes are tumor suppressorsUNIV TEXAS·Filed 2007·Granted Jul 12, 2011·1 cites·10 claims
- 5046US6905873B1Recombinant p53 adenovirus methods and compositionsUNIV TEXAS·Filed 1996·Granted Jun 14, 2005·4 cites·13 claims
Showing the top 50 of 57 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Jack A. Roth files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →